Home・Elenco Azioni・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Chiusa

SettoreSettore sanitario

12.83 3.05

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.67

Massimo

13.1

Metriche Chiave
By Trading Economics
Entrata	-107M -203M
Vendite	-7.4M 7.7M
EPS	-0.8
Margine di Profitto	-2,648.714
Dipendenti	377
EBITDA	-11M -105M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+68.01% upside

Dividendi
By Acuity
Utili prossimi	4 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	189M 1.7B
Apertura precedente	9.78
Chiusura precedente	12.83

Intellia Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, rebounding sharply after an initial dip. The stock aligns with positive trends in the biotechnology sector and ARK ETF.

20 ago 2026, 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19 ago 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17 ago 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14 ago 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11 ago 2026, 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10 ago 2026, 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7 ago 2026, 19:26 UTC

News

Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6 ago 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4 ago 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3 ago 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31 lug 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30 lug 2026, 17:57 UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29 lug 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28 lug 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27 lug 2026, 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25 lug 2026, 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24 lug 2026, 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23 lug 2026, 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22 lug 2026, 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 lug 2026, 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

20 lug 2026, 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Confronto tra pari

Modifica del prezzo

Intellia Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

68.01% in crescita

Previsioni per 12 mesi

Media 20.9 USD 68.01%

Alto 49 USD

Basso 9 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Intellia Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Intellia Therapeutics Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.